We are live on ! Find out more
CASI icon

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

57 hedge funds and large institutions have $80.8M invested in CASI Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 3 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

581% more capital inflows, than outflows

Capital inflows: $39.7M | Capital outflows: $5.83M

433% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 3

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

30% more funds holding

Funds holding: 44 → 57 (+13)

4.29% more ownership

Funds ownership: 7.11% → 11.4% (+4.3%)

Holders
57
Holders Change
+13
Holders Change %
+29.55%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
27
Increased
16
Reduced
3
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.7M
2
State Street
State Street
Massachusetts
+$3.84M
3
Northern Trust
Northern Trust
Illinois
+$3.32M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.17M
5
WSC
Wellington Shields & Co
New York
+$2.2M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.78M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$881K
3
Goldman Sachs
Goldman Sachs
New York
-$743K
4
Barclays
Barclays
United Kingdom
-$286K
5
Laurion Capital Management
Laurion Capital Management
New York
-$232K

CASI Hedge Fund Activity: Q2 2018 in Review

57 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2018, worth a combined $80.8M — up 290% from $20.7M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CASI positions and 14 closed out — a net gain of 13 holders — while 16 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, cutting an estimated $2.78M.

  • 57 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2018, up from 44 in Q1 2018.
  • Funds reported $80.8M of CASI Pharmaceuticals stock for Q2 2018, up 290% quarter-over-quarter.
  • 27 funds opened new CASI Pharmaceuticals positions in Q2 2018 and 14 closed out, a net change of +13 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $15.7M added.
  • The largest CASI Pharmaceuticals seller in Q2 2018 was Millennium Management, an estimated $2.78M sold.

Based on aggregated 13F filings for Q2 2018.